Q4 2024 Knight Therapeutics Inc Earnings Call Transcript
Key Points
- Knight Therapeutics Inc (KHTRF) achieved record high revenues of over $365 million in 2024, marking 11 consecutive years of revenue growth.
- The company's key promoted products, which account for 75% of total revenues, grew by 16% over the prior year period.
- Knight Therapeutics Inc (KHTRF) expanded its pipeline with five new products, including Crexont and Jornay PM, and strengthened partnerships with companies like Helsinn.
- The company successfully launched several products, including Bijuva and Imvexxy in Canada, and Minjuvi in Brazil, contributing to its growth strategy.
- Knight Therapeutics Inc (KHTRF) signed a new contract for Ambisome with Brazil's Ministry of Health, ensuring continued revenue from this product in 2025.
- The company's adjusted EBITDA for 2024 decreased by $2 million or 4% compared to the previous year.
- Knight Therapeutics Inc (KHTRF) faced a decline in mature and branded generic products due to their life cycle and new market competitors.
- The company experienced a decrease in gross margin as a percentage of revenues, attributed to product mix changes.
- Operating expenses increased by 10% in 2024, driven by marketing, medical initiatives, and R&D costs.
- Knight Therapeutics Inc (KHTRF) anticipates a decrease in adjusted EBITDA as a percentage of revenues in 2025 due to investments in new product launches and pipeline development.
Good morning, ladies and gentlemen. My name is Sylvie, and I will be your conference operator today. Welcome to Knight Therapeutics' fourth-quarter 2024 results conference call.
Before turning the call over to Samira Sakhia, President and CEO of Knight, listeners are reminded that portions of today's discussion may, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements.
The company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect.
The company disclaims any intentions or obligations to update or revise any forward-looking statements, whether a result of new information, future events, except as required by law. We would also like to remind you that questions during today's call will be taken from analysts only.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
